Tranquillisation or asleep by 30 minutes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Aggression · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Global outcome ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects ‐ movement disorders · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether RISPERIDONE changes adverse effects: movement disorders over 24 hours compared with OTHER ANTIPSYCHOTIC: c. QUETIAPINE (very low certainty).
1 finding from 1 review
Economic outcomes ‐ not measured · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: 1. any reason, long term (>12 months) compared with QUETIAPINE ‒ short‐ and long‐term data (low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).
1 finding from 1 review
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse events: Movement disorder ‐ any extra pyramidal symptom · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse events: Specific: Mean (SD) weight increase in kg ‐ long term · patients with schizophrenia
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Specific ‐ prolactin‐related Reported by… compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review